Rocket Pharmaceuticals (9IP1) Stock Price & Analysis
9IP1 Stock Chart & Stats
- Day’s Range
- EUR 2.07 - EUR 2.07
- 52-Week Range
- EUR 1.77 - EUR 4.67
- Previous Close
- EUR 2.25
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 239.83M
- Enterprise Value
- EUR 132.69M
- Total Cash (Recent Filing)
- EUR 283.75M
- Total Debt (Recent Filing)
- EUR 24.80M
- Price to Earnings (P/E)
- ―
- Beta
- 1.26
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -0.35
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Extended Funding Runway
The expected funding runway gives Rocket time to advance its pivotal Danon disease study and broader cardiovascular pipeline without an immediate financing need. Greater liquidity supports clinical execution and reduces near-term disruption risk while milestones are pursued.
Clearer Regulatory Pathway
Regulatory alignment materially clarifies the development path for RP-A501, including the efficacy population and endpoints that could support accelerated approval. This reduces program uncertainty and strengthens the potential for a defined catalyst from clinical completion.
Conservative Balance Sheet Leverage
Relatively low leverage provides Rocket with more balance-sheet flexibility than a highly indebted development-stage company. Although the business remains loss-making, a modest debt burden can help preserve strategic options while the pipeline advances through costly clinical development.
Bears Say
No Revenue And Persistent Losses
Rocket has not yet generated revenue and continues to report substantial operating losses, reflecting its pre-commercial status and heavy research spending. Until a therapy reaches commercialization, the company lacks operating earnings to internally fund development or offset its cost base.
Sustained Cash Burn
Persistently negative operating and free cash flow means Rocket consumes cash to advance its pipeline rather than generating funds from operations. This structurally increases reliance on financing, asset monetization or other external capital as development programs progress.
Secured Financing Constraints
The new financing extends runway but also places substantially all assets under a first-priority lien and imposes cash and operating restrictions. Covenants can limit flexibility during setbacks, while lender warrants add a potential source of future shareholder dilution.
Rocket Pharmaceuticals News
9IP1 FAQ
What was Rocket Pharmaceuticals’s price range in the past 12 months?
What is Rocket Pharmaceuticals’s market cap?
When is Rocket Pharmaceuticals’s upcoming earnings report date?
How were Rocket Pharmaceuticals’s earnings last quarter?
Is Rocket Pharmaceuticals overvalued?
Does Rocket Pharmaceuticals pay dividends?
What is Rocket Pharmaceuticals’s EPS estimate?
How many shares outstanding does Rocket Pharmaceuticals have?
What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Rocket Pharmaceuticals Stock Smart Score
Company Description
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia. Complementing these, Rocket Pharmaceuticals also has an in vivo adeno-associated virus program underway for Danon disease, a serious multi-organ lysosomal storage disorder that tragically often results in early mortality due to heart failure. To facilitate its extensive research and development efforts, the company has established key licensing partnerships with esteemed institutions such as the Fred Hutchinson Cancer Research Center, European research bodies including CIEMAT and its collaborators (Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz), UCL Business PLC (in conjunction with CIEMAT), The Regents of the University of California, and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. maintains its primary corporate location in Cranbury, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gaurav D. Shah
- Employees
- 202
- Website
- rocketpharma.com
- Address
- 9 Cedarbrook Drive, Cranbury, NJ, 08512, US
Rocket Pharmaceuticals (9IP1) Earnings & Revenues
9IP1 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 5 | 9 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 5 | 0 | 7 |
